RxDoctor Payments Data

Susan Neese, MD

Internal Medicine · Amarillo, TXNPI 1396820528

Payments from drug & device makers

$219,778in general payments, 2019–2025

Across 402 payments — averaging $546.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$214K
  • Novo Nordisk$580
  • Abbott$569
  • AstraZeneca$556
  • AbbVie$453
  • GSK$379
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$5,307100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$219,778 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$775,603
Medicare patients
825
Services billed
20,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$202,086
MounjaroTirzepatide90$95,434
JardianceEmpagliflozin75$72,873
FarxigaDapagliflozin Propanediol102$72,543
Repatha SureclickEvolocumab78$48,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$47,619
EliquisApixaban43$44,472
Soliqua 100-33Insulin Glargine/Lixisenatide48$40,103
Xigduo XrDapaglifloz Propaned/Metformin36$39,499
Bydureon BciseExenatide Microspheres18$26,033
XareltoRivaroxaban34$24,568
WegovySemaglutide17$23,984
Praluent PenAlirocumab37$21,134
Repatha SyringeEvolocumab18$19,550
LinzessLinaclotide30$17,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$580$226,070199 claims
Lilly USA, LLCMounjaro, Trulicity$105$112,051106 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$356$93,350104 claims
AstraZenecaFarxiga, Symbicort$556$76,863119 claims
GSKTrelegy Ellipta, Breo Ellipta$379$59,88391 claims
PfizerEliquis, Premarin$299$50,96956 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$88$40,10348 claims
Johnson & JohnsonXarelto$191$24,56834 claims
AbbVieLinzess, Synthroid$453$21,76688 claims
NovartisEntresto$131$11,77218 claims
Astellas Pharma US IncMyrbetriq$55$6,29113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →